Leerink Partnrs Upgrades Progyny (NASDAQ:PGNY) to Strong-Buy

Progyny (NASDAQ:PGNY - Get Free Report) was upgraded by Leerink Partnrs from a "hold" rating to a "strong-buy" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. Leerink Partnrs also issued estimates for Progyny's Q2 2025 earnings at $0.18 EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.64 EPS and FY2026 earnings at $0.98 EPS.

Several other brokerages also recently commented on PGNY. Canaccord Genuity Group cut their price target on shares of Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a report on Monday, May 12th. Leerink Partners upgraded Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price objective on the stock in a research report on Tuesday. Finally, BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective on the stock in a research report on Monday, March 31st. Five analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Progyny has a consensus rating of "Moderate Buy" and an average target price of $24.09.

Progyny Price Performance

Shares of NASDAQ:PGNY traded down $0.40 during trading on Tuesday, hitting $23.21. 739,927 shares of the company were exchanged, compared to its average volume of 1,715,109. The company has a market cap of $1.99 billion, a PE ratio of 40.72, a P/E/G ratio of 2.50 and a beta of 1.31. The stock has a 50 day moving average of $21.81 and a 200 day moving average of $21.47. Progyny has a 52-week low of $13.39 and a 52-week high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). The company had revenue of $324.04 million for the quarter, compared to analysts' expectations of $307.86 million. Progyny had a return on equity of 10.90% and a net margin of 4.33%. The company's revenue was up 16.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.17 EPS. Sell-side analysts forecast that Progyny will post 0.6 EPS for the current fiscal year.

Insider Activity

In other news, Director Cheryl Scott sold 2,675 shares of the firm's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total transaction of $59,037.25. Following the transaction, the director directly owned 14,112 shares of the company's stock, valued at approximately $311,451.84. This trade represents a 15.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 9.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PGNY. Signaturefd LLC grew its stake in shares of Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after buying an additional 1,355 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Progyny during the first quarter valued at about $44,000. Militia Capital Partners LP grew its stake in shares of Progyny by 100.0% during the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company's stock valued at $45,000 after buying an additional 1,000 shares during the last quarter. Natixis bought a new position in shares of Progyny during the fourth quarter valued at about $69,000. Finally, Brooklyn Investment Group grew its stake in shares of Progyny by 5,216.4% in the first quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock worth $72,000 after purchasing an additional 3,182 shares during the last quarter. 94.93% of the stock is owned by institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.